CTLA4 and cancer: When an inhibitory antibody is targeted to the immune checkpoints of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death protein 1 (PD-1), it can restore immune competence in cancer patients (Wang Y. et al., 2021).